Green Cross Corp (GC Biopharma) stock (KR7006280002): Kiwoom upgrade and Curevo sale reshape outlook

Green Cross Corp (GC Biopharma) drew renewed attention on the Korea Exchange on 05/28/2026 after a local broker upgraded the stock and highlighted the impact of a recently announced asset sale to U.S. pharma major Eli Lilly.

According to a report from Kiwoom Securities cited by local financial media on 05/28/2026, the house raised its investment opinion on GC Biopharma to Buy from Outperform and lifted its 12-month target price to 210,000 won from 180,000 won, pointing to a potential re-rating following the disposal of its U.S. vaccine affiliate Curevo to Eli Lilly.

The analyst note was published against the backdrop of GC Biopharma’s shares closing at 150,200 won on the Korea Exchange under code 006280, up 4.89% on the day, as shown on a South Korea equities overview as of the latest trading session.

Separate coverage of the transaction indicates that GC Biopharma expects proceeds of around ?459.9 billion, equivalent to roughly $305.9 million at current exchange rates, from the Curevo sale.

While Eli Lilly framed the deal as part of a broader 5.7 trillion won package to acquire three infectious disease-focused companies, including the GC Green Cross subsidiary, the transaction also frees up capital at GC Biopharma that could be redeployed into its core plasma and vaccine businesses.

The South Korea angle is central because GC Biopharma is headquartered in the country and listed primarily on the Korea Exchange, where domestic brokerages such as Kiwoom play an important role in shaping sentiment around midsize healthcare names.

In the local context, the Kiwoom call arrives after GC Biopharma’s share price had already risen about 5% in the prior session, adding roughly 81.8 billion won in market capitalization, suggesting that investors were starting to price in the Curevo announcement even before the formal rating upgrade.

For German-based investors who access Korean equities via off-exchange trading, GC Biopharma is also available on platforms such as Tradegate under its international identifier, typically quoted in euros based on the stock’s won-denominated price, although liquidity and spreads can differ from the home market.

From a corporate finance standpoint, the approximately ?459.9 billion cash inflow from Curevo provides GC Biopharma with additional flexibility in managing its balance sheet, potentially affecting leverage metrics, funding for pipeline projects, or shareholder-return policies in the medium term.

Management has not yet published a detailed capital allocation plan tied to the Curevo proceeds as of 05/28/2026, but Kiwoom’s thesis implies that the market may start to value GC Biopharma more as a focused plasma and vaccine player rather than a conglomerate structure with overseas biotech affiliates.

For now, the key determinants of the equity story include execution on core biologics manufacturing, demand for vaccines and plasma-derived therapies in Asia and beyond, and the timing and magnitude of any reinvestment or distribution of the Curevo sale proceeds.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

Green Cross Corp (GC Biopharma): core business model

GC Biopharma positions itself as a specialized South Korean biopharma group focused on plasma-derived products and vaccines, generating revenue primarily from supplying these biologics to domestic and overseas healthcare systems.

Industry trends and competitive position

The global vaccines and plasma-derived products industry has seen steady demand growth in recent years, driven by aging populations, heightened awareness of infectious disease risks, and the expansion of immunization programs in emerging markets, factors that frame the operating environment for GC Biopharma.

Within South Korea, GC Biopharma competes with local and international pharma and biotech companies across vaccines and biologics, but the company’s established manufacturing footprint and history in plasma products give it a recognized position in supplying key therapies to hospitals and public health authorities, which may be reinforced by a streamlined portfolio after the Curevo divestment.

Conclusion

The combination of Kiwoom Securities raising its rating and target price for GC Biopharma and the expected ?459.9 billion in proceeds from the sale of Curevo to Eli Lilly has given the stock a fresh catalyst on the Korea Exchange.

How the company allocates the incoming capital and executes on its core plasma and vaccine operations within a competitive global biopharma landscape will likely shape investor perceptions in the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.